ES2144019T3 - Composicion farmaceutica que contiene inhibidores de glucosidasa y/o de amilasa, y un inhibidor de lipasa. - Google Patents

Composicion farmaceutica que contiene inhibidores de glucosidasa y/o de amilasa, y un inhibidor de lipasa.

Info

Publication number
ES2144019T3
ES2144019T3 ES94111436T ES94111436T ES2144019T3 ES 2144019 T3 ES2144019 T3 ES 2144019T3 ES 94111436 T ES94111436 T ES 94111436T ES 94111436 T ES94111436 T ES 94111436T ES 2144019 T3 ES2144019 T3 ES 2144019T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
composition containing
lipase inhibitor
amylase inhibitors
glucosidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94111436T
Other languages
English (en)
Inventor
Klaus-Dieter Bremer
Pavel Sawlewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2144019T3 publication Critical patent/ES2144019T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PREPARADO FARMACEUTICO, CONTENIENDO COMO SUSTANCIA ACTIVA UN INHIBIDOR DE GLUCOSIDASA Y/O AMILASA Y UN INHIBIDOR LIPASA Y LAS SUSTANCIAS SOPORTE FARMACEUTICAS HABITUALES.
ES94111436T 1993-08-05 1994-07-22 Composicion farmaceutica que contiene inhibidores de glucosidasa y/o de amilasa, y un inhibidor de lipasa. Expired - Lifetime ES2144019T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH233993 1993-08-05

Publications (1)

Publication Number Publication Date
ES2144019T3 true ES2144019T3 (es) 2000-06-01

Family

ID=4231504

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94111436T Expired - Lifetime ES2144019T3 (es) 1993-08-05 1994-07-22 Composicion farmaceutica que contiene inhibidores de glucosidasa y/o de amilasa, y un inhibidor de lipasa.

Country Status (24)

Country Link
US (1) US5643874A (es)
EP (1) EP0638317B1 (es)
JP (1) JP2780932B2 (es)
KR (1) KR100342285B1 (es)
CN (1) CN1076196C (es)
AT (1) ATE190503T1 (es)
AU (1) AU684793B2 (es)
BR (1) BR9403170A (es)
CA (1) CA2128044C (es)
CZ (1) CZ286202B6 (es)
DE (1) DE59409200D1 (es)
DK (1) DK0638317T3 (es)
ES (1) ES2144019T3 (es)
GR (1) GR3033643T3 (es)
HU (1) HU222346B1 (es)
IL (1) IL110510A (es)
NO (1) NO313490B1 (es)
NZ (1) NZ264142A (es)
PL (1) PL175997B1 (es)
PT (1) PT638317E (es)
RU (1) RU2141844C1 (es)
SA (1) SA94150156B1 (es)
TW (1) TW381025B (es)
ZA (1) ZA945673B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
YU34199A (sh) * 1997-02-05 2002-08-12 F. Hoffmann-La Roche Ag. Primena inhibitora gastrointestinalne lipaze
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
DE19802700A1 (de) * 1998-01-24 1999-07-29 Bayer Ag Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält
WO2000009122A1 (en) * 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
NZ510311A (en) 1998-09-08 2003-08-29 Smithkline Beecham Corp Lipstatin derivative - soluble fiber tablets
AU2542500A (en) * 1999-01-22 2000-08-07 Hunza Di Maria Carmela Marazzita S.A.S. Lipoprotein complexes and compositions containing them
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US6235305B1 (en) * 1999-10-29 2001-05-22 2Pro Chemical Essentially nonabsorbable lipase inhibitor derivatives, pharmaceutical compositions and methods of use therefor
US6342519B2 (en) * 1999-10-29 2002-01-29 2 Pro Chemical Oxetanone derivatives
CA2358921A1 (en) * 1999-10-29 2001-05-10 John Jason Gentry Mullins Oxetanone derivatives
US6348492B1 (en) * 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
KR100349334B1 (ko) * 1999-12-08 2002-08-21 박관화 아카비오신 글루코실 시몬진 및 그것의 제조방법.
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
MXPA03000694A (es) * 2000-07-28 2003-06-04 Hoffmann La Roche Nuevo uso de los inhibidores de lipasa.
PT1307264E (pt) 2000-07-28 2005-02-28 Hoffmann La Roche Nova composicao farmaceutica
US6849609B2 (en) * 2001-04-10 2005-02-01 James U. Morrison Method and composition for controlled release acarbose formulations
AU2002362061A1 (en) 2001-12-04 2003-06-17 Biogal Gyogyszergyar Rt Preparation of orlistat and orlistat crystalline forms
US7108869B2 (en) * 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
FI20045076L (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
US20060185357A1 (en) * 2004-05-07 2006-08-24 Kovacevich Ian D Independently drawing and tensioning lines with bi-directional rotary device having two spools
EP3263118B1 (en) 2004-05-10 2019-09-25 University of Copenhagen Flaxseeds for body weight management
US20060029567A1 (en) * 2004-08-04 2006-02-09 Bki Holding Corporation Material for odor control
ATE439347T1 (de) * 2004-11-23 2009-08-15 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
US20070009615A1 (en) * 2005-04-29 2007-01-11 Litao Zhong Compositions and methods for controlling glucose uptake
WO2006132440A1 (ja) * 2005-06-09 2006-12-14 Takeda Pharmaceutical Company Limited 固形製剤
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
CN100349614C (zh) * 2005-10-21 2007-11-21 南京工业大学 一种含α－淀粉酶抑制剂的固体混合物及其制备工艺和在制药中的应用
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
MEP6808A (xx) * 2006-02-23 2010-02-10 Lundbeck & Co As H Priperidinoilpirodolini agonisti receptora menalokortina tipa 4
CL2007002958A1 (es) * 2006-10-12 2008-05-09 Epix Delaware Inc Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
EP2084127A1 (en) 2006-11-13 2009-08-05 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
KR20090083477A (ko) * 2006-11-20 2009-08-03 그렌마크 파머수티칼스 에스. 아. 스테아로일-ＣｏＡ 불포화효소 저해제인 아세틸렌 유도체
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
SI2002825T1 (sl) * 2007-06-14 2013-10-30 Krka Farmacevtski sestavki, ki obsegajo orlistat
EP2190303A1 (en) * 2007-09-12 2010-06-02 Københavns Universitet Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
MX2010004072A (es) * 2007-10-15 2010-09-14 Inventis Dds Pvt Ltd Composicion farmaceutica de orlistat.
CA2708364A1 (en) 2007-12-11 2009-06-18 Efrat Ben-Zeev Carboxamide compounds and their use as chemokine receptor agonists
US8592403B2 (en) * 2008-08-06 2013-11-26 Pfizer Limited Diazepine and diazocane compounds as MC4 agonists
RU2441654C2 (ru) * 2010-02-17 2012-02-10 Лабораториос Баго С.А. Фармацевтическая композиция с активностью против ожирения, включающая премикс чистого орлистата, и способ ее изготовления
JP5752359B2 (ja) * 2010-02-25 2015-07-22 富士フイルム株式会社 体重増加抑制組成物及びこれを含む食品
EP2571860A1 (en) 2010-05-21 2013-03-27 Pfizer Inc 2-phenyl benzoylamides
TR201100148A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Stabil akarboz förmülasyonları.
US20130345392A1 (en) 2011-03-04 2013-12-26 Pfizer Inc Edn3-like peptides and uses thereof
CN102805744A (zh) * 2011-06-02 2012-12-05 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
CN102872062A (zh) * 2011-07-13 2013-01-16 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
US8252312B1 (en) * 2011-12-27 2012-08-28 David Wong Oral solid composition comprising a lipid absorption inhibitor
US20150050371A1 (en) 2012-03-09 2015-02-19 Biotropics Malaysia Berhad Extract Formulations of Rhodamnia Cinerea And Uses Thereof
WO2013167995A2 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of hyperglycemia
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
FR3017536B1 (fr) 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
DK3233066T3 (da) * 2014-12-17 2022-01-10 Empros Pharma Ab Orlistat- og acarbosepræparat med modificeret frigivelse til behand-ling af obesitas og relaterede metaboliske lidelser
KR101903150B1 (ko) 2016-09-12 2018-10-01 가톨릭대학교산학협력단 퀴니자린을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
CN107308154A (zh) * 2017-07-19 2017-11-03 重庆植恩药业有限公司 治疗或预防肥胖症以及代谢综合征的药物组合物及其应用
CR20210441A (es) 2019-01-18 2022-03-11 Astrazeneca Ab Inhibidores de la pcsk9 y métodos de uso de los mismos

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
JPS5953920B2 (ja) * 1977-12-28 1984-12-27 東洋醸造株式会社 新規なアミノ糖化合物およびその製法
CA1121290A (en) * 1978-02-14 1982-04-06 Yasuji Suhara Amino sugar derivatives
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
ZA824382B (en) * 1981-07-07 1984-02-29 Wyeth John & Brother Ltd Anti-obesity agents
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
FI844289A7 (fi) * 1984-01-21 1985-07-22 Hoechst Ag Uusia polypeptidejä, joilla on -amylaasi-estävä vaikutus, niiden käyttö ja farmaseuttiset valmistee
US4632925A (en) * 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
SU1697823A1 (ru) * 1988-08-01 1991-12-15 Киевский государственный институт усовершенствования врачей Способ лечени алиментарно-конституционального ожирени
CA1329127C (en) * 1988-08-22 1994-05-03 Takao Matsuo Calcium absorption promoter
DK244090D0 (da) * 1990-10-09 1990-10-09 Novo Nordisk As Kemiske forbindelser
US5240962A (en) * 1991-04-15 1993-08-31 Takasago Institute For Interdisciplinary Science, Inc. Antiobesity and fat-reducing agents
GB9122051D0 (en) * 1991-10-17 1991-11-27 Univ Nottingham Medicines

Also Published As

Publication number Publication date
DK0638317T3 (da) 2000-06-26
BR9403170A (pt) 1995-04-18
RU94028653A (ru) 1996-09-10
PT638317E (pt) 2000-07-31
TW381025B (en) 2000-02-01
RU2141844C1 (ru) 1999-11-27
IL110510A (en) 1999-03-12
GR3033643T3 (en) 2000-10-31
HU9402249D0 (en) 1994-09-28
EP0638317A1 (de) 1995-02-15
PL304557A1 (en) 1995-02-06
HUT68300A (en) 1995-06-28
DE59409200D1 (de) 2000-04-20
KR100342285B1 (ko) 2002-10-25
CZ182594A3 (en) 1995-02-15
CA2128044A1 (en) 1995-02-06
HU222346B1 (hu) 2003-06-28
NO942900L (no) 1995-02-06
AU6883994A (en) 1995-02-16
AU684793B2 (en) 1998-01-08
KR950005319A (ko) 1995-03-20
EP0638317B1 (de) 2000-03-15
JP2780932B2 (ja) 1998-07-30
NO942900D0 (es) 1994-08-04
US5643874A (en) 1997-07-01
SA94150156B1 (ar) 2005-05-15
CA2128044C (en) 2007-02-20
NZ264142A (en) 1996-11-26
ATE190503T1 (de) 2000-04-15
JPH0753409A (ja) 1995-02-28
CN1106701A (zh) 1995-08-16
CN1076196C (zh) 2001-12-19
PL175997B1 (pl) 1999-03-31
IL110510A0 (en) 1994-11-11
NO313490B1 (no) 2002-10-14
ZA945673B (en) 1995-02-07
CZ286202B6 (cs) 2000-02-16

Similar Documents

Publication Publication Date Title
ES2144019T3 (es) Composicion farmaceutica que contiene inhibidores de glucosidasa y/o de amilasa, y un inhibidor de lipasa.
NO962269D0 (no) Enzyminhibitorer
PT722439E (pt) Inibidores da protease de hiv
IL110752A0 (en) Pharmaceutical composition for an hiv protease inhibitor
TR199501472A2 (tr) Matriks metaloproteaz inhibitörler.
DK0572166T3 (da) Hidtil ukendte 7beta-substitueret-4-aza-5beta-androstan-3-oner som 5beta-reduktaseinhibitorer
FI954963A7 (fi) Poly-1-n-alkeeniamiineja ja näitä sisältäviä poltto- ja voiteluainekoo stumuksia
FI961857A7 (fi) Matriksin metalloproteaasien inhibiittorit
DE59608323D1 (de) Transdermal applizierbares arzneimittel mit ace-hemmern
FI962022A7 (fi) 5,6-dihydropyronijohdannaiset proteaasi-inhibiittoreina ja antiviraali sina aineina
EP0648421A3 (en) New propellant composition.
FI962488A7 (fi) HIV:n proteaasin inhibiittoreita
FI960482A7 (fi) Matriksin metalloproteaasien inhibiittorit
FI962021A7 (fi) 5,6-dihydropyronijohdannaiset proteaasi-inhibiittoreina ja antiviraali sina aineina
EP0629348A3 (en) New propellant composition.
DE69427238D1 (de) Lager
GB2324091B (en) Metalloproteinase inhibitors
EP0614970A3 (de) Inhibitoren der Hydroxyphenylpyruvat-Dioxygenase sowie Nachweisverfahren zur Identifizierung des Enzyms.
ATE228760T1 (de) Thrombininhibitoren
NZ320259A (en) Deodorizing preparations containing cationic biopolymers, aluminium hydrochlorate and esterase inhibitors
ZA966885B (en) Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors.
EP0687473A4 (es)
FI20095141A7 (fi) Amylaasivariantit
DE69205157D1 (de) Abgedichtetes Lager.
AU5907294A (en) Amylase inhibitors

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 638317

Country of ref document: ES